View Single Post
Old 08-19-2021, 02:31 PM   #1
Nguyen
Senior Member
 
Join Date: Nov 2005
Posts: 351
Association of Antineoplastic Therapy With Decreased SARS-CoV-2 Infection Rates in Pa

Afinitor/Everolimus is an mtor inhibitor; Apelisib/Piqray inhibits the alpha isoform of pik3; Xeloda/Capecitabine, gemzar/gemcitabine, 5Fu, etc are antimetabolites.

Nguyen

Association of Antineoplastic Therapy With Decreased SARS-CoV-2 Infection Rates in Patients With Cancer

https://jamanetwork.com/journals/jam...tm_term=081921

Question Will patients with cancer treated with antineoplastic compounds associated with lower angiotensin-converting enzyme 2 (ACE2) expression exhibit lower SARS-CoV-2 infection rates?

Findings In an in silico analysis of the Library of Integrated Network-Based Cellular Signatures database, 91 compounds were associated with gene downregulation of the ACE2 entry receptor for SARS-CoV-2, including mTOR/PI3K inhibitors and antimetabolites. Patients who received a potential ACE2-lowering antineoplastic exhibited a statistically significantly reduced SARS-CoV-2 positivity rate of 7.0% compared with 12.9% in patients who received other antineoplastic therapies.

Meaning Potential ACE2-lowering antineoplastics, including mTOR/PI3K inhibitors and antimetabolites, may exhibit clinical anti–SARS-CoV-2 activity.
Nguyen is offline   Reply With Quote